Argatroban in adult extracorporeal membrane oxygenation

Nicklett Johnston, Michael Wait, Lynne Huber

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


This case report addresses the use of Argatroban, an anticoagulant and thrombin inhibitor for treatment of thrombocytopenia in an adult patient on extracorporeal membrane oxygenation (ECMO). After 5 days on ECMO, the patient showed signs of heparin-induced thrombocytopenia (HIT) with a platelet count of 20K. Argatroban was initiated to decrease progression of HIT and continue treatment with ECMO proved to be successful. Given the occurrence of HIT with heparin therapy, a need for alternate drug therapy is required for patients requiring treatment with ECMO. The use of Argatroban in adult ECMO is outlined and includes dosage, monitoring, and patient treatment.

Original languageEnglish (US)
Pages (from-to)281-284
Number of pages4
JournalJournal of Extra-Corporeal Technology
Issue number4
StatePublished - Dec 2002


  • Activated partial thromboplastin time
  • Extracorporeal membrane oxygenation
  • Thrombin time
  • Thrombocytopenia

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Health Professions (miscellaneous)
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Argatroban in adult extracorporeal membrane oxygenation'. Together they form a unique fingerprint.

Cite this